Trevi Therapeutics Inc TRVI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
2.73UNCH (UNCH)
Volume
1,229
Close
2.73UNCH (UNCH)
Volume
80,473
52 week range
0.97 - 4.00
Loading...
  • Open2.75
  • Day High2.78
  • Day Low2.59
  • Prev Close2.73
  • 52 Week High4.00
  • 52 Week High Date03/21/24
  • 52 Week Low0.97
  • 52 Week Low Date11/27/23

Key Stats

  • Market Cap192.288M
  • Shares Out70.44M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta0.90
  • YTD % Change103.73

KEY STATS

  • Open2.75
  • Day High2.78
  • Day Low2.59
  • Prev Close2.73
  • 52 Week High4.00
  • 52 Week High Date03/21/24
  • 52 Week Low0.97
  • 52 Week Low Date11/27/23
  • Market Cap192.288M
  • Shares Out70.44M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta0.90
  • YTD % Change103.73

RATIOS/PROFITABILITY

  • EPS (TTM)-0.34
  • P/E (TTM)-8.08
  • Fwd P/E (NTM)-6.72
  • EBITDA (TTM)-38.127M
  • ROE (TTM)-38.57%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.17%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Trevi Therapeutics Inc

 

Profile

MORE
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and...
David Meeker M.D.
Non-Executive Chairman of the Board
Jennifer Good
President, Chief Executive Officer, Director
Lisa Delfini CPA
Chief Financial Officer
Address
195 Church St Fl 14
New Haven, CT
06510-2009
United States

Top Peers

SYMBOLLASTCHG%CHG
PRLD
Prelude Therapeutics Inc
3.80+0.07+1.88%
DSGN
Design Therapeutics Inc
4.55-0.02-0.44%
ABOS
Acumen Pharmaceuticals Inc
3.36UNCHUNCH
ATOS
Atossa Therapeutics Inc
1.46-0.03-2.01%
OVID
Ovid Therapeutics Inc
3.02+0.02+0.67%